Context Therapeutics Inc. CNTX
We take great care to ensure that the data presented and summarized in this overview for Context Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CNTX
View all-
Nextech Invest Ag7.42MShares$7.57 Million2.37% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.42MShares$7.57 Million0.54% of portfolio
-
Avidity Partners Management LP Dallas, TX7.42MShares$7.57 Million0.89% of portfolio
-
Great Point Partners LLC Greenwich, CT6.93MShares$7.07 Million6.28% of portfolio
-
Blue Owl Capital Holdings LP New York, NY5.41MShares$5.52 Million3.5% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.74MShares$3.82 Million0.0% of portfolio
-
Blackstone Inc New York, NY2.44MShares$2.49 Million0.02% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT1.94MShares$1.97 Million0.23% of portfolio
-
Franklin Resources Inc San Mateo, CA1.85MShares$1.89 Million0.0% of portfolio
-
Ally Bridge Group (Ny) LLC New York, NY1.76MShares$1.79 Million2.45% of portfolio
Latest Institutional Activity in CNTX
Top Purchases
Top Sells
About CNTX
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Insider Transactions at CNTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 21
2023
|
Martin A. Lehr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,823
+3.52%
|
$0
$0.84 P/Share
|
|
Feb 13
2023
|
Martin A. Lehr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,606
+3.52%
|
$0
$0.87 P/Share
|
|
Feb 06
2023
|
Martin A. Lehr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,040
+3.29%
|
$0
$0.97 P/Share
|
|
Jan 30
2023
|
Martin A. Lehr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
7,027
+4.68%
|
$0
$0.7 P/Share
|
|
Jan 23
2023
|
Martin A. Lehr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
6,839
+4.78%
|
$0
$0.72 P/Share
|
|
Jan 17
2023
|
Martin A. Lehr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
6,783
+4.98%
|
$0
$0.74 P/Share
|
|
Dec 16
2022
|
Martin A. Lehr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+14.03%
|
$0
$0.74 P/Share
|
|
Dec 16
2022
|
Jennifer Lynn Minai Azary Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+38.46%
|
$0
$0.74 P/Share
|
|
Dec 09
2022
|
Alex C. Levit Chief Legal Officer, Corp. Sec |
BUY
Open market or private purchase
|
Direct |
6,000
+40.0%
|
$0
$0.85 P/Share
|
|
Aug 19
2022
|
Martin A. Lehr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
13,000
+11.25%
|
$13,000
$1.85 P/Share
|
|
Aug 17
2022
|
Jennifer Lynn Minai Azary Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$15,000
$1.8 P/Share
|
|
Aug 16
2022
|
Tarek Sahmoud Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$10,000
$1.95 P/Share
|
|
Dec 16
2021
|
Martin A. Lehr Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
13,000
+1.56%
|
$39,000
$3.22 P/Share
|
|
Oct 22
2021
|
Evan G. Dick |
BUY
Conversion of derivative security
|
Direct |
26,587
+23.38%
|
-
|
|
Oct 22
2021
|
Martin A. Lehr Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
797,198
+42.64%
|
-
|
|
Oct 22
2021
|
Martin A. Lehr Chief Executive Officer |
BUY
Exercise of out-of-the-money derivative securities
|
Indirect |
52,680
+50.0%
|
$368,760
$7.14 P/Share
|
|
Oct 22
2021
|
Martin A. Lehr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+9.13%
|
$50,000
$5.0 P/Share
|
|
Oct 22
2021
|
Alex C. Levit Chief Legal Officer, Corp. Sec |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$15,000
$5.0 P/Share
|